All In Biotech

Free tool

FAERS Monitor: Ziac

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020186 or its brand name (Ziac, Bisoprolol Fumarate, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.

Reports

620

Serious

443

71% of reports

Hospitalization

263

Death reported

54

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache50
  • fatigue44
  • drug ineffective43
  • nausea42
  • pruritus39
  • pain38
  • hypertension37
  • vomiting36
  • diarrhoea33
  • rash33
  • dyspnoea32
  • arthralgia31
  • hypersensitivity31
  • off label use30
  • dizziness29

Reports by year received

View as table
YearReports
200422
200539
200618
200733
200841
200942
201075
201164
201295
20135
20147
201512
201620
201719
201824
201914
202012
202115
202215
20238
202414
202514
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,539 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypertensionSignal375.94.3148
hypersensitivitySignal315.74.0116
pruritusSignal393.42.566
headacheSignal502.72.154
vomitingSignal362.61.935
rashSignal332.61.831
arthralgiaSignal312.51.828
painSignal382.11.521
dizziness292.01.413
dyspnoea321.91.414
fatigue441.91.419
nausea421.81.315
diarrhoea331.71.210
off label use301.20.81
drug ineffective431.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.